{"schema_version":"1.0","type":"article","title":"台灣生技估值第一步：不要把所有公司都塞進同一個本益比","url":"https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.md","lang":"zh-Hant","date":"2026-05-27","publish_at":"2026-05-27T10:30:00+08:00","updated_at":"2026-05-27","category":"商業分析系列","topic":"生技估值","tags":["生技估值","本益比","rNPV","SOTP"],"summary":"台灣生技股最常見的錯誤，不是模型算錯一點，而是公司類型一開始就分錯。","key_points":[],"facts":[],"sections":["五種生技資產","為什麼本益比不夠","台康這類公司為什麼難估"],"references":[],"images":[{"alt":"台灣生技估值框架：先分辨公司資產類型，再選模型與追蹤事件。","url":"https://drugnews.com.tw/assets/articles/taiwan-biotech-valuation-framework/valuation-map.svg"}],"cover_image":"https://drugnews.com.tw/assets/articles/taiwan-biotech-valuation-framework/valuation-map.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-27）。台灣生技估值第一步：不要把所有公司都塞進同一個本益比。https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-27-taiwan-biotech-valuation-framework-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}